Año 2020 / Volumen 112 / Número 10
Original
Cut-off ranges of infliximab serum levels in Crohn’s disease in the clinical practice

756-761

DOI: 10.17235/reed.2020.6539/2019

Teresa Valdés Delgado, María Fernanda Guerra Veloz, Luisa Castro Laria, Belén Maldonado Pérez, Raúl Perea Amarillo, Vicente Merino Bohórquez, Antonia Sáez, Ángel Caunedo Álvarez, Federico Argüelles Arias,

Resumen
Introduction: between 30 % and 40 % of patients treated with infliximab lose response during maintenance. Therapeutic drug monitoring could be used to optimize management in these situations. However, infliximab serum levels are not well defined. The aim of this study was to determine the cut-off range of infliximab serum levels in Crohn’s disease patients in remission in the clinical practice. Methods: an observational retrospective study was performed from 2016 to 2017. Patients were included with established Crohn’s disease, who had been on a maintenance dose schedule of infliximab. Infliximab levels and antibodies to infliximab were measured at least twice in all patients, after induction and after six months of treatment. Clinical remission was defined as ≤ 4 using the Harvey-Bradshaw index. Cluster analysis was used to analyze the results. Results: one hundred and five Crohn’s disease patients were included in the study; 57.1 % were male with a mean age of 39 years (SD ± 12.9). The median (range) time of the disease was eleven years (7-15) and the median (range) time of follow-up was 32 months (22-38). Patients who achieved remission had infliximab serum levels between 4.26-8.26 ug/ml versus 0.06-1.43 ug/ml in patients who did not achieve remission after induction. Infliximab serum levels were 2.84-7.75 ug/ml and 0.05-2.69 ug/ml in patients who achieved remission versus those who did not achieve remission after six months of treatment. Overall, 4.26-8.26 ug/ml was found to be the best cut-off range for remission. Conclusions: in our clinical practice, serum levels of infliximab in Crohn’s disease patients should be higher than 4 ug/ml to achieve clinical remission.
Share Button
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Instrucciones para citar
Valdés Delgado T, Guerra Veloz M, Castro Laria L, Maldonado Pérez B, Perea Amarillo R, Merino Bohórquez V, et all. Cut-off ranges of infliximab serum levels in Crohn’s disease in the clinical practice. 6539/2019


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 639 veces.
Este artículo ha sido descargado 179 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 29/07/2019

Aceptado: 23/01/2020

Prepublicado: 21/09/2020

Publicado: 07/10/2020

Tiempo de revisión del artículo: 164 días

Tiempo de prepublicación: 420 días

Tiempo de edición del artículo: 436 días


Compartir
Este artículo ha sido valorado por 2 lectores .
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2023 y Creative Commons. Revista Española de Enfermedades Digestivas